(Q42627458)

English

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

scientific article published on May 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15150304%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15150304%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Tadeusz Pieńkowski

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15150304%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

author name string

Mark D Pegram

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15150304%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Donald W Northfelt

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15150304%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Wolfgang Eiermann

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15150304%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Ravi Patel

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15150304%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Pierre Fumoleau

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15150304%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Eleonor Quan

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15150304%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

John Crown

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15150304%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Deborah Toppmeyer

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15150304%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Michael Smylie

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15150304%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Alessandro Riva

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15150304%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Sandra Blitz

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15150304%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Michael F Press

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15150304%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

David Reese

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15150304%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Mary-Ann Lindsay

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15150304%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Dennis J Slamon

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15150304%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

language of work or name

0 references

publication date

1 May 2004

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15150304%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Journal of the National Cancer Institute

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15150304%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

96

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15150304%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

759-769

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15150304%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15150304%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH133

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH133

21 January 2018

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH133

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH133

21 January 2018

Cardiac dysfunction in the trastuzumab clinical trials experience

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH133

21 January 2018

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH133

21 January 2018

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH133

21 January 2018

Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH133

21 January 2018

Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH133

21 January 2018

Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH133

21 January 2018

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH133

21 January 2018

Docetaxel in combination with carboplatin for chemo-naive patients with epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH133

21 January 2018

Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH133

21 January 2018

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH133

21 January 2018

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH133

21 January 2018

Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH133

21 January 2018

Estimation of glomerular filtration rate in cancer patients

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH133

21 January 2018

The use of the Calvert formula to determine the optimal carboplatin dosage

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH133

21 January 2018

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH133

21 January 2018

A model-based approach for assessing in vivo combination therapy interactions

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH133

21 January 2018

Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH133

21 January 2018

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH133

21 January 2018

Identifiers

10.1093/JNCI/DJH133

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15150304%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15150304%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42627458&oldid=1577703466"